Somira Health Review

What Somira Health charges

• Sermorelin: $179.99/mo — Monthly Plan, per month; the seller also prints "$149.99 / month ($449.99 / quarter)" on a quarterly plan, which is its own division of the quarterly total
• NAD+: $199.99/mo — Monthly Plan, per month; the seller also prints "$163.33 / month ($489.99 / quarter)" on a quarterly plan, which is its own division of the quarterly total

The compounder, named, above the price table

The pricing block is headed with a single sentence naming the pharmacy that compounds every longevity and metabolic-support treatment it sells.

That is a name, not a license class, and it is on the same surface as the figures rather than buried in terms.

The footer separately publishes the operating company and a street address.

Between them, a reader can look up both the seller and the facility, which is rare enough here to be the reason to read this one.

Two plans per compound, and the arithmetic is shown

Each compound is offered on a monthly plan and a quarterly plan, and both are printed.

The quarterly plan prints a per-month figure with the quarterly total in brackets immediately beside it.

That bracket is the seller doing its own division in public, which is more honest than a bare per-month number and still not a rate anyone is billed.

This row records the monthly plan figures, which are billed as printed; the quarterly ones sit in the qualifier beside them.

Whose fifty states

Its FAQ asks what states it serves and answers that its affiliated prescribing providers are licensed in all fifty.

The very next sentence says the company is currently available only where compliant pharmacy fulfilment is also available.

So the fifty-state clause describes the prescribers, and the seller itself withdraws it as a coverage claim one sentence later.

No list of the states where fulfilment actually exists is published anywhere on the pages read.

The rest of the record

Lab work is not described as included in what is charged.

Two of the compounds this site tracks are sold, so anything else means a second seller.

Two nonsense paths were fired at this host in the same run as everything above, and both returned 404 with a short error page.

The federal warning-letter record was screened by brand and by the operating company in the footer, with a positive and a negative control in the same run, and returned nothing.

How we verified this

• Rendered every page cited on this row in a real browser engine and read the laid-out text nodes, so nothing here rests on markup that never reaches a reader.
• Fired two nonsense-path controls at this host in the same run — one at the root and one inside the section the priced pages live in — and compared the address requested with the address actually served.
• Joined every text node before scanning for a dollar sign, so a figure split across nested elements could not read as an absence.
• Screened this seller in the live federal warning-letter record by brand and, where an operating company is published, by entity — pulling the whole table and filtering locally, because that endpoint's own search parameter is silently ignored.
• Ran a known-good positive control and a nonsense negative control against that table in the same run, and read the company column of every returned record rather than accepting a full-text match.
• Read both sentences of the state answer and rested nothing on the first, because it describes the prescribers' licensure and the second withdraws it for the company.
• Recorded the monthly plan figures rather than the quarterly per-month ones, because the latter are the seller's own division of a quarterly total it also prints.
• Read the sentence above the price table as the pharmacy disclosure it is, and confirmed it names a facility rather than a license class.